Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Pittet, MJ; Speiser, DE; Valmori, D; Rimoldi, D; Lienard, D; Lejeune, F; Cerottini, JC; Romero, P
   Ex vivo analysis of tumor antigen specific CD8(+) T cell responses using MHC/peptide tetramers in cancer patients
   INTERNATIONAL IMMUNOPHARMACOLOGY
   
   M.J. Pittet et al., "Ex vivo analysis of tumor antigen specific CD8(+) T cell responses using MHC/peptide tetramers in cancer patients", INT IMMUNO, 1(7), 2001, pp. 1235-1247
2. Pittet, MJ; Speiser, DE; Lienard, D; Valmori, D; Guillaume, P; Dutoit, V; Rimoldi, D; Lejeune, F; Cerottini, JC; Romero, P
   Expansion and functional maturation of human tumor antigen-specific CD8(+)T cells after vaccination with antigenic peptide
   CLINICAL CANCER RESEARCH
   
   M.J. Pittet et al., "Expansion and functional maturation of human tumor antigen-specific CD8(+)T cells after vaccination with antigenic peptide", CLIN CANC R, 7(3), 2001, pp. 796S-803S
3. Vouillamoz-Lorenz, S; Bauer, J; Lejeune, F; Decosterd, LA
   Validation of an AAS method for the determination of platinum in biological fluids from patients receiving the oral platinum derivative JM216
   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
   
   S. Vouillamoz-Lorenz et al., "Validation of an AAS method for the determination of platinum in biological fluids from patients receiving the oral platinum derivative JM216", J PHARM B, 25(3-4), 2001, pp. 465-475
4. Brand, M; Moggs, JG; Oulad-Abdelghani, M; Lejeune, F; Dilworth, FJ; Stevenin, J; Almouzni, G; Tora, L
   UV-damaged DNA-binding protein in the TFTC complex links DNA damage recognition to nucleosome acetylation
   EMBO JOURNAL
   
   M. Brand et al., "UV-damaged DNA-binding protein in the TFTC complex links DNA damage recognition to nucleosome acetylation", EMBO J, 20(12), 2001, pp. 3187-3196
5. Rubio-Godoy, V; Dutoit, V; Rimoldi, D; Lienard, D; Lejeune, F; Speiser, D; Guillaume, P; Cerottini, JC; Romero, P; Valmori, D
   Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life
   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
   
   V. Rubio-Godoy et al., "Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life", P NAS US, 98(18), 2001, pp. 10302-10307
6. Millan, MJ; Gobert, A; Lejeune, F; Newman-Tancredi, A; Rivet, JM; Auclair, A; Peglion, JL
   S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine
   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
   
   M.J. Millan et al., "S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine", J PHARM EXP, 298(2), 2001, pp. 565-580
7. Millan, MJ; Cussac, D; Milligan, G; Carr, C; Audinot, V; Gobert, A; Lejeune, F; Rivet, JM; Brocco, M; Duqueyroix, D; Nicolas, JP; Boutin, JA; Newman-Tancredi, A
   Antiparkinsonian agent piribedil displays antagonist properties at native,rat, and cloned, human alpha(2)-adrenoceptors: Cellular and functional characterization
   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
   
   M.J. Millan et al., "Antiparkinsonian agent piribedil displays antagonist properties at native,rat, and cloned, human alpha(2)-adrenoceptors: Cellular and functional characterization", J PHARM EXP, 297(3), 2001, pp. 876-887
8. Millan, MJ; Lejeune, F; De Nanteuil, G; Gobert, A
   Selective blockade of neurokinin (NK)(1) receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats
   JOURNAL OF NEUROCHEMISTRY
   
   M.J. Millan et al., "Selective blockade of neurokinin (NK)(1) receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats", J NEUROCHEM, 76(6), 2001, pp. 1949-1954
9. Pittet, MJ; Zippelius, A; Speiser, DE; Assenmacher, M; Guillaume, P; Valmori, D; Lienard, D; Lejeune, F; Cerottini, JC; Romero, P
   Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: Implicationsof a novel approach for T cell monitoring in infectious and malignant diseases
   JOURNAL OF IMMUNOLOGY
   
   M.J. Pittet et al., "Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: Implicationsof a novel approach for T cell monitoring in infectious and malignant diseases", J IMMUNOL, 166(12), 2001, pp. 7634-7640
10. Le Guienr, C; Lejeune, F; Galiana, D; Kister, L; Breathnach, R; Stevenin, J; Del Gatto-Konczak, F
    TIA-1 and TIAR activate splicing of alternative exons with weak 5 ' splicesites followed by a U-rich stretch on their own pre-mRNAs
    JOURNAL OF BIOLOGICAL CHEMISTRY
    
    C. Le Guienr et al., "TIA-1 and TIAR activate splicing of alternative exons with weak 5 ' splicesites followed by a U-rich stretch on their own pre-mRNAs", J BIOL CHEM, 276(44), 2001, pp. 40638-40646
11. Lejeune, F; Cavaloc, Y; Stevenin, J
    Alternative splicing of intron 3 of the serine/arginine-rich protein 9G8 gene - Identification of flanking exonic splicing enhancers and involvement of 9G8 as a trans-acting factor
    JOURNAL OF BIOLOGICAL CHEMISTRY
    
    F. Lejeune et al., "Alternative splicing of intron 3 of the serine/arginine-rich protein 9G8 gene - Identification of flanking exonic splicing enhancers and involvement of 9G8 as a trans-acting factor", J BIOL CHEM, 276(11), 2001, pp. 7850-7858
12. Ghanem, G; Loir, B; Morandini, R; Sales, F; Lienard, D; Eggermont, A; Lejeune, F
    On the release and half-life of S100B protein in the peripheral blood of melanoma patients
    INTERNATIONAL JOURNAL OF CANCER
    
    G. Ghanem et al., "On the release and half-life of S100B protein in the peripheral blood of melanoma patients", INT J CANC, 94(4), 2001, pp. 586-590
13. Speiser, DE; Migliaccio, M; Pittet, MJ; Valmori, D; Lienard, D; Lejeune, F; Reichenbach, P; Guillaume, P; Luscher, I; Cerottini, JC; Romero, P
    Human CD8(+) T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells
    EUROPEAN JOURNAL OF IMMUNOLOGY
    
    D.E. Speiser et al., "Human CD8(+) T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells", EUR J IMMUN, 31(2), 2001, pp. 459-466
14. Lejeune, F; Millan, MJ
    Pindolol excites dopaminergic and adrenergic neurons, and inhibits serotonergic neurons, by activation of 5-HT1A receptors
    EUROPEAN JOURNAL OF NEUROSCIENCE
    
    F. Lejeune e M.J. Millan, "Pindolol excites dopaminergic and adrenergic neurons, and inhibits serotonergic neurons, by activation of 5-HT1A receptors", EUR J NEURO, 12(9), 2000, pp. 3265-3275
15. Millan, MJ; Gobert, A; Rivet, JM; Adhumeau-Auclair, A; Cussac, D; Newman-Tancredi, A; Dekeyne, A; Nicolas, JP; Lejeune, F
    Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha(2)-adrenergic and serotonin(2C) receptors: a comparison with citalopram
    EUROPEAN JOURNAL OF NEUROSCIENCE
    
    M.J. Millan et al., "Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha(2)-adrenergic and serotonin(2C) receptors: a comparison with citalopram", EUR J NEURO, 12(3), 2000, pp. 1079-1095
16. Gobert, A; Rivet, JM; Lejeune, F; Newman-Tancredi, A; Adhumeau-Auclair, A; Nicolas, JP; Cistarelli, L; Melon, C; Millan, MJ
    Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat
    SYNAPSE
    
    A. Gobert et al., "Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat", SYNAPSE, 36(3), 2000, pp. 205-221
17. Millan, MJ; Newman-Tancredi, A; Audinot, V; Cussac, D; Lejeune, F; Nicolas, JP; Coge, F; Galizzi, JP; Boutin, JA; Rivet, JM; Dekeyne, A; Gobert, A
    Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT1B, 5-HT1D and dopamine D-2 and D-3 receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states
    SYNAPSE
    
    M.J. Millan et al., "Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT1B, 5-HT1D and dopamine D-2 and D-3 receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states", SYNAPSE, 35(2), 2000, pp. 79-95
18. Millan, MJ; Lejeune, F; Gobert, A
    Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents
    JOURNAL OF PSYCHOPHARMACOLOGY
    
    M.J. Millan et al., "Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents", J PSYCHOPH, 14(2), 2000, pp. 114-138
19. Millan, MJ; Lejeune, F; Gobert, A; Brocco, M; Auclair, A; Bosc, C; Rivet, JM; Lacoste, JM; Cordi, A; Dekeyne, A
    S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    
    M.J. Millan et al., "S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine", J PHARM EXP, 295(3), 2000, pp. 1206-1222
20. Millan, MJ; Gobert, A; Newman-Tancredi, A; Lejeune, F; Cussac, D; Rivet, JM; Audinot, V; Dubuffet, T; Lavielle, G
    S33084, a novel, potent, selective, and competitive antagonist at dopamineD-3-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    
    M.J. Millan et al., "S33084, a novel, potent, selective, and competitive antagonist at dopamineD-3-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626", J PHARM EXP, 293(3), 2000, pp. 1048-1062
21. Millan, MJ; Gobert, A; Newman-Tancredi, A; Lejeune, F; Cussac, D; Rivet, JM; Audinot, V; Adhumeau, A; Brocco, M; Nicolas, JP; Boutin, JA; Despaux, N; Peglion, JL
    S18327 (1-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl}3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1) and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    
    M.J. Millan et al., "S18327 (1-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl}3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1) and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile", J PHARM EXP, 292(1), 2000, pp. 38-53
22. Rimoldi, D; Rubio-Godoy, V; Dutoit, V; Lienard, D; Salvi, S; Guillaume, P; Speiser, D; Stockert, E; Spagnoli, G; Servis, C; Cerottini, JC; Lejeune, F; Romero, P; Valmori, D
    Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma
    JOURNAL OF IMMUNOLOGY
    
    D. Rimoldi et al., "Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma", J IMMUNOL, 165(12), 2000, pp. 7253-7261
23. Valmori, D; Dutoit, V; Lienard, D; Lejeune, F; Speiser, D; Rimoldi, D; Cerundolo, V; Dietrich, PY; Cerottini, JC; Romero, P
    Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8(+) T cells in melanoma patients
    JOURNAL OF IMMUNOLOGY
    
    D. Valmori et al., "Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8(+) T cells in melanoma patients", J IMMUNOL, 165(1), 2000, pp. 533-538
24. Valmori, D; Dutoit, V; Lienard, D; Rimoldi, D; Pittet, MJ; Champagne, P; Ellefsen, K; Sahin, U; Speiser, D; Lejeune, F; Cerottini, JC; Romero, P
    Naturally occurring human lymphocyte antigen-A2 restricted CD8+T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients
    CANCER RESEARCH
    
    D. Valmori et al., "Naturally occurring human lymphocyte antigen-A2 restricted CD8+T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients", CANCER RES, 60(16), 2000, pp. 4499-4506
25. Kettaneh, A; Fain, O; Ziol, M; Lejeune, F; Eclache-Saudreau, V; Biaggi, A; Guettier-Bouttier, C; Thomas, M
    Minocycline-induced systemic adverse reaction with liver and bone marrow granulomas and Sezary-like cells
    AMERICAN JOURNAL OF MEDICINE
    
    A. Kettaneh et al., "Minocycline-induced systemic adverse reaction with liver and bone marrow granulomas and Sezary-like cells", AM J MED, 108(4), 2000, pp. 353-354
26. Ruegg, C; Oguey, D; Lejeune, F
    Death to endothelial cells, death to melanoma?
    MELANOMA RESEARCH
    
    C. Ruegg et al., "Death to endothelial cells, death to melanoma?", MELANOMA RE, 9(1), 1999, pp. 2-3
27. Gander, M; Leyvraz, S; Decosterd, L; Bonfanti, M; Marzolini, C; Shen, F; Lienard, D; Perey, L; Colella, G; Biollaz, J; Lejeune, F; Yarosh, D; Belanich, M; D'Incalci, M
    Sequential administration of temozolomide and fotemustine: Depletion of O-6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours
    ANNALS OF ONCOLOGY
    
    M. Gander et al., "Sequential administration of temozolomide and fotemustine: Depletion of O-6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours", ANN ONCOL, 10(7), 1999, pp. 831-838
28. Marzolini, C; Decosterd, LA; Shen, F; Gander, M; Leyvraz, S; Bauer, J; Buclin, T; Biollaz, J; Lejeune, F
    Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration (vol 42, pg 433, 1998)
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    C. Marzolini et al., "Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration (vol 42, pg 433, 1998)", CANC CHEMOT, 43(5), 1999, pp. 439-440
29. Pittet, MJ; Valmori, D; Dunbar, PR; Speiser, DE; Lienard, D; Lejeune, F; Fleischhauer, K; Cerundolo, V; Cerottini, JC; Romero, P
    High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals
    JOURNAL OF EXPERIMENTAL MEDICINE
    
    M.J. Pittet et al., "High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals", J EXP MED, 190(5), 1999, pp. 705-715
30. Valmori, D; Pittet, MJ; Rimoldi, D; Lienard, D; Dunbar, R; Cerundolo, V; Lejeune, F; Cerottini, JC; Romero, P
    An antigen-targeted approach to adoptive transfer therapy of cancer
    CANCER RESEARCH
    
    D. Valmori et al., "An antigen-targeted approach to adoptive transfer therapy of cancer", CANCER RES, 59(9), 1999, pp. 2167-2173
31. Decosterd, LA; Cottin, E; Chen, X; Lejeune, F; Mirimanoff, RO; Biollaz, J; Coucke, PA
    Simultaneous determination of deoxyribonucleoside in the presence of ribonucleoside triphosphates in human carcinoma cells by high-performance liquidchromatography
    ANALYTICAL BIOCHEMISTRY
    
    L.A. Decosterd et al., "Simultaneous determination of deoxyribonucleoside in the presence of ribonucleoside triphosphates in human carcinoma cells by high-performance liquidchromatography", ANALYT BIOC, 270(1), 1999, pp. 59-68
32. ANDRIEU JM; JAIS JP; COLONNA P; DESABLENS B; BRIERE J; FRANCOIS S; HAROUSSEAU JL; CASASSUS P; LEMEVEL A; LEPRISE PY; GHANDOUR C; GUILHOT F; LEJEUNE F
    10-YEAR RESULTS OF A STRATEGY COMBINING 3 CYCLES OF ABVD AND HIGH-DOSE EXTENDED IRRADIATION FOR TREATING HODGKINS-DISEASE AT ADVANCED STAGES
    Annals of oncology
    
    J.M. Andrieu et al., "10-YEAR RESULTS OF A STRATEGY COMBINING 3 CYCLES OF ABVD AND HIGH-DOSE EXTENDED IRRADIATION FOR TREATING HODGKINS-DISEASE AT ADVANCED STAGES", Annals of oncology, 9(2), 1998, pp. 195-203
33. VOUILLAMOZLORENZ S; DECOSTERD LA; BAUER J; BUCLIN T; LEJEUNE F
    A PHASE-I PHARMACOKINETIC (PK) STUDY OF THE ORAL PLATINUM (PT) ANALOGJM216 ADMINISTERED ONCE-A-DAY OVER 14 DAYS
    Annals of oncology
    
    S. Vouillamozlorenz et al., "A PHASE-I PHARMACOKINETIC (PK) STUDY OF THE ORAL PLATINUM (PT) ANALOGJM216 ADMINISTERED ONCE-A-DAY OVER 14 DAYS", Annals of oncology, 9, 1998, pp. 500-500
34. LEJEUNE F; MILLAN MJ
    INDUCTION OF BURST FIRING IN VENTRAL TEGMENTAL AREA DOPAMINERGIC-NEURONS BY ACTIVATION OF SEROTONIN (5-HT)(1A) RECEPTORS - WAY 100,635-REVERSIBLE ACTIONS OF THE HIGHLY SELECTIVE LIGANDS, FLESINOXAN AND S-15535
    Synapse
    
    F. Lejeune e M.J. Millan, "INDUCTION OF BURST FIRING IN VENTRAL TEGMENTAL AREA DOPAMINERGIC-NEURONS BY ACTIVATION OF SEROTONIN (5-HT)(1A) RECEPTORS - WAY 100,635-REVERSIBLE ACTIONS OF THE HIGHLY SELECTIVE LIGANDS, FLESINOXAN AND S-15535", Synapse, 30(2), 1998, pp. 172-180
35. MARZOLINI C; DECOSTERD LA; SHEN F; GANDER M; LEYVRAZ S; BAUER J; BUCLIN T; BIOLLAZ J; LEJEUNE F
    PHARMACOKINETICS OF TEMOZOLOMIDE IN ASSOCIATION WITH FOTEMUSTINE IN MALIGNANT-MELANOMA AND MALIGNANT GLIOMA PATIENTS - COMPARISON OF ORAL, INTRAVENOUS, AND HEPATIC INTRAARTERIAL ADMINISTRATION
    Cancer chemotherapy and pharmacology
    
    C. Marzolini et al., "PHARMACOKINETICS OF TEMOZOLOMIDE IN ASSOCIATION WITH FOTEMUSTINE IN MALIGNANT-MELANOMA AND MALIGNANT GLIOMA PATIENTS - COMPARISON OF ORAL, INTRAVENOUS, AND HEPATIC INTRAARTERIAL ADMINISTRATION", Cancer chemotherapy and pharmacology, 42(6), 1998, pp. 433-440
36. MILLAN MJ; NEWMANTANCREDI A; BROCCO N; GOBERT A; LEJEUNE F; AUDINOT V; RIVET JM; SCHREIBER R; DEKEYNE A; SPEDDING M; NICOLAS JP; PEGLION JL
    S-18126 4-(2,3-DIHYDROBENZO[1,4]DIOXIN-6-YL)PIPERAZIN-1-YL METHYL]INDAN-2-YL)), A POTENT, SELECTIVE AND COMPETITIVE ANTAGONIST AT DOPAMINE D-4 RECEPTORS - AN IN-VITRO AND IN-VIVO COMPARISON WITH L-745,870 YL]PIPERAZIN-1-YL)METHYL-1H-PYRROLO[2,3B]PYRIDINE) AND RACLOPRIDE
    The Journal of pharmacology and experimental therapeutics
    
    M.J. Millan et al., "S-18126 4-(2,3-DIHYDROBENZO[1,4]DIOXIN-6-YL)PIPERAZIN-1-YL METHYL]INDAN-2-YL)), A POTENT, SELECTIVE AND COMPETITIVE ANTAGONIST AT DOPAMINE D-4 RECEPTORS - AN IN-VITRO AND IN-VIVO COMPARISON WITH L-745,870 YL]PIPERAZIN-1-YL)METHYL-1H-PYRROLO[2,3B]PYRIDINE) AND RACLOPRIDE", The Journal of pharmacology and experimental therapeutics, 287(1), 1998, pp. 167-186
37. AUDINOT V; NEWMANTANCREDI A; GOBERT A; RIVET JM; BROCCO M; LEJEUNE F; GLUCK L; DESPOSTE I; BERVOETS K; DEKEYNE A; MILLAN MJ
    A COMPARATIVE IN-VITRO AND IN-VIVO PHARMACOLOGICAL CHARACTERIZATION OF THE NOVEL DOPAMINE D-3 RECEPTOR ANTAGONISTS (-S-14297, NAFADOTRIDE, GR-103,691 AND U-99194())
    The Journal of pharmacology and experimental therapeutics
    
    V. Audinot et al., "A COMPARATIVE IN-VITRO AND IN-VIVO PHARMACOLOGICAL CHARACTERIZATION OF THE NOVEL DOPAMINE D-3 RECEPTOR ANTAGONISTS (-S-14297, NAFADOTRIDE, GR-103,691 AND U-99194())", The Journal of pharmacology and experimental therapeutics, 287(1), 1998, pp. 187-197
38. MILLAN MJ; GOBERT A; NEWMANTANCREDI A; AUDINOT V; LEJEUNE F; RIVET JM; CUSSAC D; NICOLAS JP; MULLER O; LAVIELLE G
    S-16924 YL]-PYRROLIDIN-3YL)-1-(4-FLUORO-PHENYL)-ETHANONE), A NOVEL POTENTIAL ANTIPSYCHOTIC WITH MARKED SEROTONIN (5-HT)(1A) AGONIST PROPERTIES - I - RECEPTORIAL AND NEUROCHEMICAL PROFILE COMPARISON WITH CLOZAPINE AND HALOPERIDOL
    The Journal of pharmacology and experimental therapeutics
    
    M.J. Millan et al., "S-16924 YL]-PYRROLIDIN-3YL)-1-(4-FLUORO-PHENYL)-ETHANONE), A NOVEL POTENTIAL ANTIPSYCHOTIC WITH MARKED SEROTONIN (5-HT)(1A) AGONIST PROPERTIES - I - RECEPTORIAL AND NEUROCHEMICAL PROFILE COMPARISON WITH CLOZAPINE AND HALOPERIDOL", The Journal of pharmacology and experimental therapeutics, 286(3), 1998, pp. 1341-1355
39. DSOUZA S; RIMOLDI D; LIENARD D; LEJEUNE F; CEROTTINI JC; ROMERO P
    CIRCULATING MELAN-A MART-1 SPECIFIC CYTOLYTIC T-LYMPHOCYTE PRECURSORSIN HLA-A2(+) MELANOMA PATIENTS HAVE A MEMORY PHENOTYPE/
    International journal of cancer
    
    S. Dsouza et al., "CIRCULATING MELAN-A MART-1 SPECIFIC CYTOLYTIC T-LYMPHOCYTE PRECURSORSIN HLA-A2(+) MELANOMA PATIENTS HAVE A MEMORY PHENOTYPE/", International journal of cancer, 78(6), 1998, pp. 699-706
40. NAJEAN Y; RAIN JD; LEJEUNE F; ECHARD M; FERMAND JP; GRUYER P; BRAHIMI S
    TREATMENT OF POLYCYTHEMIA - II - RANDOMIZ ED PROTOCOL IN POLYCYTHEMIA-VERA PATIENTS COMPARING HYDROXYUREA AND PIPOBROMAN
    Annales de medecine interne
    
    Y. Najean et al., "TREATMENT OF POLYCYTHEMIA - II - RANDOMIZ ED PROTOCOL IN POLYCYTHEMIA-VERA PATIENTS COMPARING HYDROXYUREA AND PIPOBROMAN", Annales de medecine interne, 149(2), 1998, pp. 94-100
41. LEJEUNE F; LIENARD D; EGGERMONT A
    REGIONAL ADMINISTRATION OF RECOMBINANT TUMOR-NECROSIS-FACTOR-ALPHA INCANCER, WITH SPECIAL REFERENCE TO MELANOMA
    Biodrugs
    
    F. Lejeune et al., "REGIONAL ADMINISTRATION OF RECOMBINANT TUMOR-NECROSIS-FACTOR-ALPHA INCANCER, WITH SPECIAL REFERENCE TO MELANOMA", Biodrugs, 9(3), 1998, pp. 211-218
42. KEILHOLZ U; STOTER G; PUNT CJA; SCHEIBENBOGEN C; LEJEUNE F; EGGERMONT AMM
    RECOMBINANT INTERLEUKIN-2-BASED TREATMENTS FOR ADVANCED MELANOMA - THE EXPERIENCE OF THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER MELANOMA COOPERATIVE GROUP
    The cancer journal from Scientific American
    
    U. Keilholz et al., "RECOMBINANT INTERLEUKIN-2-BASED TREATMENTS FOR ADVANCED MELANOMA - THE EXPERIENCE OF THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER MELANOMA COOPERATIVE GROUP", The cancer journal from Scientific American, 3, 1997, pp. 22-28
43. WAANDERS GA; RIMOLDI D; LIENARD D; CARREL S; LEJEUNE F; DIETRICH PY; CEROTTINI JC; ROMERO P
    MELANOMA-REACTIVE HUMAN CYTOTOXIC T-LYMPHOCYTES DERIVED FROM SKIN BIOPSIES OF DELAYED-TYPE HYPERSENSITIVITY REACTIONS INDUCED BY INJECTION OF AN AUTOLOGOUS MELANOMA CELL-LINES (VOL 3, PG 685, 1997)
    Clinical cancer research
    
    G.A. Waanders et al., "MELANOMA-REACTIVE HUMAN CYTOTOXIC T-LYMPHOCYTES DERIVED FROM SKIN BIOPSIES OF DELAYED-TYPE HYPERSENSITIVITY REACTIONS INDUCED BY INJECTION OF AN AUTOLOGOUS MELANOMA CELL-LINES (VOL 3, PG 685, 1997)", Clinical cancer research, 3(9), 1997, pp. 1676-1676
44. WAANDERS GA; RIMOLDI D; LIENARD D; CARREL S; LEJEUNE F; DIETRICH PY; CEROTTINI JC; ROMERO P
    MELANOMA-REACTIVE HUMAN CYTOTOXIC T-LYMPHOCYTES DERIVED FROM SKIN BIOPSIES OF DELAYED-TYPE HYPERSENSITIVITY REACTIONS INDUCED BY INJECTION OF AN AUTOLOGOUS MELANOMA CELL-LINE
    Clinical cancer research
    
    G.A. Waanders et al., "MELANOMA-REACTIVE HUMAN CYTOTOXIC T-LYMPHOCYTES DERIVED FROM SKIN BIOPSIES OF DELAYED-TYPE HYPERSENSITIVITY REACTIONS INDUCED BY INJECTION OF AN AUTOLOGOUS MELANOMA CELL-LINE", Clinical cancer research, 3(5), 1997, pp. 685-696
45. GERAIN J; LIENARD D; PAMPALLONA S; BAUMGARTNER M; RUEGG C; BUURMAN WA; EGGERMONT A; LEJEUNE F
    SYSTEMIC RELEASE OF SOLUBLE TNF RECEPTORS AFTER HIGH-DOSE TNF IN ISOLATED LIMB PERFUSION
    Cytokine
    
    J. Gerain et al., "SYSTEMIC RELEASE OF SOLUBLE TNF RECEPTORS AFTER HIGH-DOSE TNF IN ISOLATED LIMB PERFUSION", Cytokine, 9(12), 1997, pp. 1034-1042
46. LEJEUNE F; KOOPS HS; KROON B; EGGERMONT A
    REGIONAL THERAPY FOR MELANOMA - RANDOMIZED TRIALS
    European journal of cancer
    
    F. Lejeune et al., "REGIONAL THERAPY FOR MELANOMA - RANDOMIZED TRIALS", European journal of cancer, 33, 1997, pp. 1315-1315
47. LEYVRAZ S; SPATARO V; BAUER J; PAMPALLONA S; SALMON R; DORVAL T; MEULI R; GILLET M; LEJEUNE F; ZOGRAFOS L
    TREATMENT OF OCULAR MELANOMA METASTATIC TO THE LIVER BY HEPATIC ARTERIAL CHEMOTHERAPY
    Journal of clinical oncology
    
    S. Leyvraz et al., "TREATMENT OF OCULAR MELANOMA METASTATIC TO THE LIVER BY HEPATIC ARTERIAL CHEMOTHERAPY", Journal of clinical oncology, 15(7), 1997, pp. 2589-2595
48. LEJEUNE F; NEWMANTANCREDI A; AUDINOT V; MILLAN MJ
    INTERACTIONS OF (-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN AND (-)-8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN AND 7-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN AT HUMAN (H)D-3, HD(2) AND H-SEROTONIN(1A) RECEPTORS AND THEIR MODULATION OF THE ACTIVITY OF SEROTONINERGIC AND DOPAMINERGIC-NEURONS IN RATS())
    The Journal of pharmacology and experimental therapeutics
    
    F. Lejeune et al., "INTERACTIONS OF (-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN AND (-)-8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN AND 7-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN AT HUMAN (H)D-3, HD(2) AND H-SEROTONIN(1A) RECEPTORS AND THEIR MODULATION OF THE ACTIVITY OF SEROTONINERGIC AND DOPAMINERGIC-NEURONS IN RATS())", The Journal of pharmacology and experimental therapeutics, 280(3), 1997, pp. 1241-1249
49. AUTIER P; DORE JF; GEFELLER O; CESARINI JP; LEJEUNE F; KOELMEL KF; LIENARD D; KLEEBERG UR
    MELANOMA RISK AND RESIDENCE IN SUNNY AREAS
    British Journal of Cancer
    
    P. Autier et al., "MELANOMA RISK AND RESIDENCE IN SUNNY AREAS", British Journal of Cancer, 76(11), 1997, pp. 1521-1524
50. TCHERNIA G; LEJEUNE F; BOCCARA JF; DENAVIT MF; DOMMERGUES JP; BERNAUDIN F
    ERYTHROBLASTIC AND OR MEGAKARYOBLASTIC LEUKEMIA IN DOWN-SYNDROME - TREATMENT WITH LOW-DOSE ARABINOSYL CYTOSINE/
    Journal of pediatric hematology/oncology
    
    G. Tchernia et al., "ERYTHROBLASTIC AND OR MEGAKARYOBLASTIC LEUKEMIA IN DOWN-SYNDROME - TREATMENT WITH LOW-DOSE ARABINOSYL CYTOSINE/", Journal of pediatric hematology/oncology, 18(1), 1996, pp. 59-62
51. NAJEAN Y; RAIN JD; DRESCH C; GOGUEL A; LEJEUNE F; ECHARD M; GRANGE MJ
    RISK OF LEUKEMIA, CARCINOMA, AND MYELOFIBROSIS IN P-32-TREATED OR CHEMOTHERAPY-TREATED PATIENTS WITH POLYCYTHEMIA-VERA - A PROSPECTIVE ANALYSIS OF 682 CASES
    Leukemia & lymphoma
    
    Y. Najean et al., "RISK OF LEUKEMIA, CARCINOMA, AND MYELOFIBROSIS IN P-32-TREATED OR CHEMOTHERAPY-TREATED PATIENTS WITH POLYCYTHEMIA-VERA - A PROSPECTIVE ANALYSIS OF 682 CASES", Leukemia & lymphoma, 22, 1996, pp. 111-119
52. BENHAMOU M; FEUILLARD J; LORTHOLARY O; BOURGEOIS C; MICHEL L; LEGOFF L; MICHEL A; MENCIAHUERTA JM; LEJEUNE F; CASASSUS P; DEBRE P; AROCK M
    PROTEIN-TYROSINE KINASES IN ACTIVATION SIGNAL OF HUMAN BASOPHILS THROUGH THE IMMUNOGLOBULIN-E RECEPTOR-TYPE-I
    Journal of leukocyte biology
    
    M. Benhamou et al., "PROTEIN-TYROSINE KINASES IN ACTIVATION SIGNAL OF HUMAN BASOPHILS THROUGH THE IMMUNOGLOBULIN-E RECEPTOR-TYPE-I", Journal of leukocyte biology, 59(3), 1996, pp. 461-470
53. FAIN O; MATHIEU E; FETON N; SIBONY M; SITBON M; LEJEUNE F; THOMAS M
    INTESTINAL INVOLVEMENT IN SWEETS-SYNDROME
    Journal of the American Academy of Dermatology
    
    O. Fain et al., "INTESTINAL INVOLVEMENT IN SWEETS-SYNDROME", Journal of the American Academy of Dermatology, 35(6), 1996, pp. 989-990
54. GOBERT A; LEJEUNE F; RIVET JM; CISTARELLI L; MILLAN MJ
    DOPAMINE D-3 (AUTO) RECEPTORS INHIBIT DOPAMINE RELEASE IN THE FRONTAL-CORTEX OF FREELY MOVING RATS IN-VIVO
    Journal of neurochemistry
    
    A. Gobert et al., "DOPAMINE D-3 (AUTO) RECEPTORS INHIBIT DOPAMINE RELEASE IN THE FRONTAL-CORTEX OF FREELY MOVING RATS IN-VIVO", Journal of neurochemistry, 66(5), 1996, pp. 2209-2212
55. SHEN F; DECOSTERD LA; GANDER M; LEYVRAZ S; BIOLLAZ J; LEJEUNE F
    DETERMINATION OF TEMOZOLOMIDE IN HUMAN PLASMA AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY AFTER SOLID-PHASE EXTRACTION
    Journal of chromatography B. Biomedical applications
    
    F. Shen et al., "DETERMINATION OF TEMOZOLOMIDE IN HUMAN PLASMA AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY AFTER SOLID-PHASE EXTRACTION", Journal of chromatography B. Biomedical applications, 667(2), 1995, pp. 291-300
56. KLEEBERG UR; ENGEL E; ISRAELS P; BROCKER EB; TILGEN W; KENNES C; GERARD B; LEJEUNE F; GLABBEKE MV; LENTZ MA
    PALLIATIVE THERAPY OF MELANOMA PATIENTS WITH FOTEMUSTINE - INVERSE RELATIONSHIP BETWEEN TUMOR LOAD AND TREATMENT EFFECTIVENESS - A MULTICENTER PHASE-II TRIAL OF THE EORTC-MELANOMA COOPERATIVE GROUP (MCG)
    Melanoma research
    
    U.R. Kleeberg et al., "PALLIATIVE THERAPY OF MELANOMA PATIENTS WITH FOTEMUSTINE - INVERSE RELATIONSHIP BETWEEN TUMOR LOAD AND TREATMENT EFFECTIVENESS - A MULTICENTER PHASE-II TRIAL OF THE EORTC-MELANOMA COOPERATIVE GROUP (MCG)", Melanoma research, 5(3), 1995, pp. 195-200
57. LEJEUNE F
    REGIONAL TREATMENT WITH TNF-ALPHA AND CHEMOTHERAPY
    European journal of cancer
    
    F. Lejeune, "REGIONAL TREATMENT WITH TNF-ALPHA AND CHEMOTHERAPY", European journal of cancer, 31A, 1995, pp. 4-4
58. FOURNIER D; LEJEUNE F; TOURTE Y
    CYTOLOGICAL EVENTS DURING THE INITIATION OF MERISTEMATIC NODULES IN CALLI DERIVED FROM EGGPLANT PROTOPLASTS
    Biology of the cell
    
    D. Fournier et al., "CYTOLOGICAL EVENTS DURING THE INITIATION OF MERISTEMATIC NODULES IN CALLI DERIVED FROM EGGPLANT PROTOPLASTS", Biology of the cell, 85(1), 1995, pp. 93-100
59. GOBERT A; LEJEUNE F; RIVET JM; AUDINOT V; NEWMANTANCREDI A; MILLAN MJ
    MODULATION OF THE ACTIVITY OF CENTRAL SEROTONINERGIC NEURONS BY NOVELSEROTONIN(1A) RECEPTOR AGONISTS AND ANTAGONISTS - A COMPARISON TO ADRENERGIC AND DOPAMINERGIC-NEURONS IN RATS
    The Journal of pharmacology and experimental therapeutics
    
    A. Gobert et al., "MODULATION OF THE ACTIVITY OF CENTRAL SEROTONINERGIC NEURONS BY NOVELSEROTONIN(1A) RECEPTOR AGONISTS AND ANTAGONISTS - A COMPARISON TO ADRENERGIC AND DOPAMINERGIC-NEURONS IN RATS", The Journal of pharmacology and experimental therapeutics, 273(3), 1995, pp. 1032-1046
60. MILLAN MJ; RIVET JM; AUDINOT V; GOBERT A; LEJEUNE F; BROCCO M; NEWMANTANCREDI A; MAURELREMY S; BERVOETS K
    ANTAGONIST PROPERTIES OF LY-165,163 AT PRESYNAPTIC AND POSTSYNAPTIC DOPAMINE D-2, D-3, AND D-1 RECEPTORS - MODULATION OF AGONIST ACTIONS AT5-HT1A RECEPTORS IN-VIVO
    The Journal of pharmacology and experimental therapeutics
    
    M.J. Millan et al., "ANTAGONIST PROPERTIES OF LY-165,163 AT PRESYNAPTIC AND POSTSYNAPTIC DOPAMINE D-2, D-3, AND D-1 RECEPTORS - MODULATION OF AGONIST ACTIONS AT5-HT1A RECEPTORS IN-VIVO", The Journal of pharmacology and experimental therapeutics, 273(3), 1995, pp. 1418-1427
61. BRASSEUR F; RIMOLDI D; LIENARD D; LETHE B; CARREL S; ARIENTI F; SUTER L; VANWIJCK R; BOURLOND A; HUMBLET Y; VACCA A; CONESE M; LAHAYE T; DEGIOVANNI G; DERAEMAECKER R; BEAUDUIN M; SASTRE X; SALAMON E; DRENO B; JAGER E; KNUTH A; CHEVREAU C; SUCIU S; LACHAPELLE JM; POUILLART P; PARMIANI G; LEJEUNE F; CEROTTINI JC; BOON T; MARCHAND M
    EXPRESSION OF MAGE GENES IN PRIMARY AND METASTATIC CUTANEOUS MELANOMA
    International journal of cancer
    
    F. Brasseur et al., "EXPRESSION OF MAGE GENES IN PRIMARY AND METASTATIC CUTANEOUS MELANOMA", International journal of cancer, 63(3), 1995, pp. 375-380
62. AUTIER P; DORE JF; SCHIFFLERS E; CESARINI JP; BOLLAERTS A; KOELMEL KF; GEFELLER O; LIABEUF A; LEJEUNE F; LIENARD D; JOARLETTE M; CHEMALY P; KLEEBERG UR
    MELANOMA AND USE OF SUNSCREENS - AN EORTC CASE-CONTROL STUDY IN GERMANY, BELGIUM AND FRANCE
    International journal of cancer
    
    P. Autier et al., "MELANOMA AND USE OF SUNSCREENS - AN EORTC CASE-CONTROL STUDY IN GERMANY, BELGIUM AND FRANCE", International journal of cancer, 61(6), 1995, pp. 749-755
63. LEJEUNE F; MILLAN MJ
    ACTIVATION OF DOPAMINE D-3 AUTORECEPTORS INHIBITS FIRING OF VENTRAL TEGMENTAL DOPAMINERGIC-NEURONS IN-VIVO
    European journal of pharmacology
    
    F. Lejeune e M.J. Millan, "ACTIVATION OF DOPAMINE D-3 AUTORECEPTORS INHIBITS FIRING OF VENTRAL TEGMENTAL DOPAMINERGIC-NEURONS IN-VIVO", European journal of pharmacology, 275(3), 1995, pp. 7-9
64. EGGIMANN P; CHIOLERO R; CHASSOT PG; LIENARD D; GERAIN J; LEJEUNE F
    SYSTEMIC AND HEMODYNAMIC-EFFECTS OF RECOMBINANT TUMOR-NECROSIS-FACTOR-ALPHA IN ISOLATION PERFUSION OF THE LIMBS
    Chest
    
    P. Eggimann et al., "SYSTEMIC AND HEMODYNAMIC-EFFECTS OF RECOMBINANT TUMOR-NECROSIS-FACTOR-ALPHA IN ISOLATION PERFUSION OF THE LIMBS", Chest, 107(4), 1995, pp. 1074-1082
65. LEJEUNE F; LIENARD D; EGGERMONT A; KOOPS HS; ROSENKAIMER F; GERAIN J; KLAASE J; KROON B; SCHMITZ P
    EFFICACY OF TUMOR-NECROSIS-FACTOR-ALPHA ( RTNF-ALPHA) ASSOCIATED TO INTERFERON-GAMMA (IFN-GAMMA) AND TO CHEMOTHERAPY IN ISOLATED LIMB PERFUSION FOR INOPERABLE MALIGNANT-MELANOMA, SOFT-TISSUE SARCOMA AND EPIDERMOID CARCINOMA - A 4-YEAR EXPERIENCE
    Bulletin du cancer
    
    F. Lejeune et al., "EFFICACY OF TUMOR-NECROSIS-FACTOR-ALPHA ( RTNF-ALPHA) ASSOCIATED TO INTERFERON-GAMMA (IFN-GAMMA) AND TO CHEMOTHERAPY IN ISOLATED LIMB PERFUSION FOR INOPERABLE MALIGNANT-MELANOMA, SOFT-TISSUE SARCOMA AND EPIDERMOID CARCINOMA - A 4-YEAR EXPERIENCE", Bulletin du cancer, 82(7), 1995, pp. 561-567
66. MAURELREMY S; AUDINOT V; LEJEUNE F; BERVOETS K; MILLAN MJ
    BLOCKADE OF PHENCYCLIDINE-INDUCED HYPERLOCOMOTION IN RATS BY CLOZAPINE, MDL-100,907 AND OTHER ANTIPSYCHOTICS CORRELATES WITH AFFINITY AT 5-HT2A RECEPTORS
    British Journal of Pharmacology
    
    S. Maurelremy et al., "BLOCKADE OF PHENCYCLIDINE-INDUCED HYPERLOCOMOTION IN RATS BY CLOZAPINE, MDL-100,907 AND OTHER ANTIPSYCHOTICS CORRELATES WITH AFFINITY AT 5-HT2A RECEPTORS", British Journal of Pharmacology, 114, 1995, pp. 154-154
67. BEGUIN Y; LOO M; RZIK S; SAUTOIS B; LEJEUNE F; RORIVE G; FILLET G
    QUANTITATIVE ASSESSMENT OF ERYTHROPOIESIS IN HEMODIALYSIS-PATIENTS DEMONSTRATES GRADUAL EXPANSION OF ERYTHROBLASTS DURING CONSTANT TREATMENT WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN
    British Journal of Haematology
    
    Y. Beguin et al., "QUANTITATIVE ASSESSMENT OF ERYTHROPOIESIS IN HEMODIALYSIS-PATIENTS DEMONSTRATES GRADUAL EXPANSION OF ERYTHROBLASTS DURING CONSTANT TREATMENT WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN", British Journal of Haematology, 89(1), 1995, pp. 17-23
68. LEYVRAZ S; KETTERER N; PEREY L; BAUER J; VUICHARD P; GROB JP; SCHNEIDER P; VONFLIEDNER V; LEJEUNE F; BACHMANN F
    INTENSIFICATION OF CHEMOTHERAPY FOR THE TREATMENT OF SOLID TUMORS - FEASIBILITY OF A 3-FOLD INCREASE IN DOSE INTENSITY WITH PERIPHERAL-BLOOD PROGENITOR CELLS AND GRANULOCYTE-COLONY-STIMULATING FACTOR
    British Journal of Cancer
    
    S. Leyvraz et al., "INTENSIFICATION OF CHEMOTHERAPY FOR THE TREATMENT OF SOLID TUMORS - FEASIBILITY OF A 3-FOLD INCREASE IN DOSE INTENSITY WITH PERIPHERAL-BLOOD PROGENITOR CELLS AND GRANULOCYTE-COLONY-STIMULATING FACTOR", British Journal of Cancer, 72(1), 1995, pp. 178-182
69. PETERS R; PEREZ L; JANOSSY G; PAMPALLONA S; LEJEUNE F; LEYVRAZ S
    BCL-2 PROTEIN EXPRESSION IN CD34(+) SUBPOPULATIONS
    Blood
    
    R. Peters et al., "BCL-2 PROTEIN EXPRESSION IN CD34(+) SUBPOPULATIONS", Blood, 86(10), 1995, pp. 466-466
70. FAIN O; SITBON M; SIBONY M; FRILAY Y; MATHIEU E; LEJEUNE F; THOMAS M
    SUCCESSFUL TREATMENT OF SYSTEMIC MASTOCYT OSIS WITH INTERFERON-ALPHA
    Annales de medecine interne
    
    O. Fain et al., "SUCCESSFUL TREATMENT OF SYSTEMIC MASTOCYT OSIS WITH INTERFERON-ALPHA", Annales de medecine interne, 146(3), 1995, pp. 205-206
71. LEJEUNE F; LIENARD D; EGGERMONT A; KOOPS HS; KROON B
    VALUE OF ISOLATION-INFUSIONS OF THE LIMBS IN MELANOMAS AND SARCOMAS
    Annales de chirurgie
    
    F. Lejeune et al., "VALUE OF ISOLATION-INFUSIONS OF THE LIMBS IN MELANOMAS AND SARCOMAS", Annales de chirurgie, 49(1), 1995, pp. 9-12
72. FENAUX P; MOREL P; BAUTERS F; PIGUET H; MONCONDUIT M; TILLY F; DESABLENS B; CLAISSE JF; ADJIZIAN JC; POTRON G; PIGNON B; LEPORRIER M; TROUSSARD X; REMAN O; BINET JL; DIGHIERO G; MALOUM K; MERLEBERAL H; RAPHAEL M; REISENLEITER M; LINASSIER C; LAMAGNERE JP; JAUBERT J; VASSELOM C; LEBLAY R; JACOMY D; GROSBOIS B; DREYFUS B; GUILHOT F; VAUGIER G; SOUTEYRAND P; LEPEU G; TOUCHAIS AM; BOUDJERRA N; BORDESSOULE M; SCHMIDT J; FACQUETDANIS J; SEBBAN C; ALLARD C; MURGUE B; SCHVED JF; ARNAUD A; CASSASSUS P; LEPRISE PY; DOR JF; TURPIN F; SOLALCELIGNY P; TERTIAN G; BERNARD JF; JAMES JM; REIGNER A; BLANC M; RAPP MJ; BOURGEOIS JP; LEJEUNE F; SALLES B; RENOUX M; GARIN B; CAMO J; TCHERNIA G; CECCALDI J; DEVIDAS A; LEMEVELLEPOURHIET A; BRIERE J; JANVIER M; NAJEAN Y; CHEVRET S; CHASTANG C; TRAVADE P
    IS THE CHOP REGIMEN A GOOD TREATMENT FOR ADVANCED CLL - RESULTS FROM 2 RANDOMIZED CLINICAL-TRIALS
    Leukemia & lymphoma
    
    P. Fenaux et al., "IS THE CHOP REGIMEN A GOOD TREATMENT FOR ADVANCED CLL - RESULTS FROM 2 RANDOMIZED CLINICAL-TRIALS", Leukemia & lymphoma, 13(5-6), 1994, pp. 449-456
73. VANBEEUMEN J; DEVREESE B; GHANEM G; LEJEUNE F; DEKNOP C; FAIGNET C; TOCH I; JACQUEMOTTE F
    ELECTROSPRAY MASS-SPECTROMETRIC ANALYSIS OF NEW ALPHA-MSH ANALOGS CARRYING NITROGEN-MUSTARD AT THEIR AMINO-TERMINUS
    Peptide research
    
    J. Vanbeeumen et al., "ELECTROSPRAY MASS-SPECTROMETRIC ANALYSIS OF NEW ALPHA-MSH ANALOGS CARRYING NITROGEN-MUSTARD AT THEIR AMINO-TERMINUS", Peptide research, 7(1), 1994, pp. 7-12
74. AUTIER P; DORE JF; LEJEUNE F; KOELMEL KF; GEFFELER O; HILLE P; CESARINI JP; LIENARD D; LIABEUF A; JOARLETTE M; CHEMALY P; HAKIM K; KOELN A; KLEEBERG UR
    RECREATIONAL EXPOSURE TO SUNLIGHT AND LACK OF INFORMATION AS RISK-FACTORS FOR CUTANEOUS MALIGNANT-MELANOMA - RESULTS OF AN -ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC) CASE-CONTROL STUDY IN BELGIUM, FRANCE AND GERMANY
    Melanoma research
    
    P. Autier et al., "RECREATIONAL EXPOSURE TO SUNLIGHT AND LACK OF INFORMATION AS RISK-FACTORS FOR CUTANEOUS MALIGNANT-MELANOMA - RESULTS OF AN -ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC) CASE-CONTROL STUDY IN BELGIUM, FRANCE AND GERMANY", Melanoma research, 4(2), 1994, pp. 79-85
75. BEGUIN Y; LOO M; RZIK S; SAUTOIS B; LEJEUNE F; RORIVE G; FILLET G
    EFFECT OF RECOMBINANT-HUMAN-ERYTHROPOIETIN ON PLATELETS IN PATIENTS WITH ANEMIA OF RENAL-FAILURE - CORRELATION OF PLATELET COUNT WITH ERYTHROPOIETIC ACTIVITY AND IRON PARAMETERS
    European journal of haematology
    
    Y. Beguin et al., "EFFECT OF RECOMBINANT-HUMAN-ERYTHROPOIETIN ON PLATELETS IN PATIENTS WITH ANEMIA OF RENAL-FAILURE - CORRELATION OF PLATELET COUNT WITH ERYTHROPOIETIC ACTIVITY AND IRON PARAMETERS", European journal of haematology, 53(5), 1994, pp. 265-270
76. LEJEUNE F; LIENARD D; EGGERMONT A; KOOPS HS; ROSENKAIMER F; GERAIN J; KLAASE J; KROON B; VANDERVEKEN J; SCHMITZ P
    RATIONALE FOR USING TNF-ALPHA AND CHEMOTHERAPY IN REGIONAL THERAPY OFMELANOMA
    Journal of cellular biochemistry
    
    F. Lejeune et al., "RATIONALE FOR USING TNF-ALPHA AND CHEMOTHERAPY IN REGIONAL THERAPY OFMELANOMA", Journal of cellular biochemistry, 56(1), 1994, pp. 52-61
77. LIENARD D; LEJEUNE F; CHASSOT PG; CHIOLERO R; EGGIMAN P; EGGERMONT A; KOOPS HS; KROON B
    TNF-ALPHA IN ISOLATION PERFUSION FOR LIMB TUMORS
    Pathologie et biologie
    
    D. Lienard et al., "TNF-ALPHA IN ISOLATION PERFUSION FOR LIMB TUMORS", Pathologie et biologie, 42(10), 1994, pp. 1073-1074
78. LEJEUNE F; LIENARD D; EGGERMONT A; KOOPS HS; KROON B; GERAIN J; ROSENKAIMER F; SCHMITZ P
    CLINICAL-EXPERIENCE WITH HIGH-DOSE TUMOR-NECROSIS-FACTOR-ALPHA IN REGIONAL THERAPY OF ADVANCED MELANOMA
    Circulatory shock
    
    F. Lejeune et al., "CLINICAL-EXPERIENCE WITH HIGH-DOSE TUMOR-NECROSIS-FACTOR-ALPHA IN REGIONAL THERAPY OF ADVANCED MELANOMA", Circulatory shock, 43(4), 1994, pp. 191-197
79. MILLAN MJ; CANTON H; GOBERT A; LEJEUNE F; RIVET JM; BERVOETS K; BROCCO M; WIDDOWSON P; MENNINI T; AUDINOT V; HONORE P; RENOUARD A; LEMAROUILLEGIRARDON S; VERRIELE L; GRESSIER H; PEGLION JL
    NOVEL BENZODIOXOPIPERAZINES ACTING AS ANTAGONISTS AT POSTSYNAPTIC 5-HT1A RECEPTORS AND AS AGONISTS AT 5-HT1A AUTORECEPTORS - A COMPARATIVE PHARMACOLOGICAL CHARACTERIZATION WITH PROPOSED 5-HT1A ANTAGONISTS
    The Journal of pharmacology and experimental therapeutics
    
    M.J. Millan et al., "NOVEL BENZODIOXOPIPERAZINES ACTING AS ANTAGONISTS AT POSTSYNAPTIC 5-HT1A RECEPTORS AND AS AGONISTS AT 5-HT1A AUTORECEPTORS - A COMPARATIVE PHARMACOLOGICAL CHARACTERIZATION WITH PROPOSED 5-HT1A ANTAGONISTS", The Journal of pharmacology and experimental therapeutics, 268(1), 1994, pp. 337-352
80. AUTIER P; DORE JF; LEJEUNE F; KOELMEL KF; GEFFELER O; HILLE P; CESARINI JP; LIENARD D; LIABEUF A; JOARLETTE M; CHEMALY P; HAKIM K; KOELN A; KLEEBERG UR
    CUTANEOUS MALIGNANT-MELANOMA AND EXPOSURE TO SUNLAMPS OR SUNBEDS - ANEORTC MULTICENTER CASE-CONTROL STUDY IN BELGIUM, FRANCE AND GERMANY
    International journal of cancer
    
    P. Autier et al., "CUTANEOUS MALIGNANT-MELANOMA AND EXPOSURE TO SUNLAMPS OR SUNBEDS - ANEORTC MULTICENTER CASE-CONTROL STUDY IN BELGIUM, FRANCE AND GERMANY", International journal of cancer, 58(6), 1994, pp. 809-813
81. RENARD N; LIENARD D; LESPAGNARD L; EGGERMONT A; HEIMANN R; LEJEUNE F
    EARLY ENDOTHELIUM ACTIVATION AND POLYMORPHONUCLEAR CELL INVASION PRECEDE SPECIFIC NECROSIS OF HUMAN-MELANOMA AND SARCOMA TREATED BY INTRAVASCULAR HIGH-DOSE TUMOR-NECROSIS-FACTOR-ALPHA (RTNF-ALPHA)
    International journal of cancer
    
    N. Renard et al., "EARLY ENDOTHELIUM ACTIVATION AND POLYMORPHONUCLEAR CELL INVASION PRECEDE SPECIFIC NECROSIS OF HUMAN-MELANOMA AND SARCOMA TREATED BY INTRAVASCULAR HIGH-DOSE TUMOR-NECROSIS-FACTOR-ALPHA (RTNF-ALPHA)", International journal of cancer, 57(5), 1994, pp. 656-663
82. LEJEUNE F; AUDINOT V; GOBERT A; RIVET JM; SPEDDING M; MILLAN MJ
    CLOZAPINE INHIBITS SEROTONINERGIC TRANSMISSION BY AN ACTION AT ALPHA(1)-ADRENOCEPTORS NOT AT 5-HT1A RECEPTORS
    European journal of pharmacology
    
    F. Lejeune et al., "CLOZAPINE INHIBITS SEROTONINERGIC TRANSMISSION BY AN ACTION AT ALPHA(1)-ADRENOCEPTORS NOT AT 5-HT1A RECEPTORS", European journal of pharmacology, 260(1), 1994, pp. 79-83
83. FAIN O; ELMSELMI A; DOSQUET C; MESEURE D; LEJEUNE F; GAREL JM; THOMAS M
    HYPERCALCEMIA IN B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA
    British Journal of Haematology
    
    O. Fain et al., "HYPERCALCEMIA IN B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA", British Journal of Haematology, 87(4), 1994, pp. 856-858
84. LEJEUNE F; GOBERT A; RIVET JM; MILLAN MJ
    BLOCKADE OF TRANSMISSION AT NMDA RECEPTORS FACILITATES THE ELECTRICALAND SYNTHETIC ACTIVITY OF ASCENDING SEROTONINERGIC NEURONS
    Brain research
    
    F. Lejeune et al., "BLOCKADE OF TRANSMISSION AT NMDA RECEPTORS FACILITATES THE ELECTRICALAND SYNTHETIC ACTIVITY OF ASCENDING SEROTONINERGIC NEURONS", Brain research, 656(2), 1994, pp. 427-431
85. GOASGUEN JE; MATHIOT C; ZANDECKI M; SCHEIFF JM; BIZET M; AMAR M; LEJEUNE F; GRANGE MJ; CORBERAND JX; GENTILHOMME O; FLANDRIN G
    DEMONSTRATION THAT MORPHOLOGY IS CORRELATED TO THE PROGNOSIS IN MULTIPLE-MYELOMA
    Blood
    
    J.E. Goasguen et al., "DEMONSTRATION THAT MORPHOLOGY IS CORRELATED TO THE PROGNOSIS IN MULTIPLE-MYELOMA", Blood, 84(10), 1994, pp. 10000654-10000654
86. GHANEM GE; JOUBRAN C; ARNOULD R; LEJEUNE F; FRUHLING J
    LABELED POLYCYANOACRYLATE NANOPARTICLES FOR HUMAN IN-VIVO USE
    Applied radiation and isotopes
    
    G.E. Ghanem et al., "LABELED POLYCYANOACRYLATE NANOPARTICLES FOR HUMAN IN-VIVO USE", Applied radiation and isotopes, 44(9), 1993, pp. 1219-1224
87. BINET JL; FENAUX P; MOREL P; BAUTERS F; PIGUET H; MONCONDUIT M; TILLY F; DESABLENS B; CLAISSE JF; ADJIZIAN JC; POTRON G; PIGNON B; LEPORRIER M; TROUSSARD X; REMAN O; BINET JL; MALOUM K; MERLEBERAL H; RAPHAEL M; REISENLEITER M; LINASSIER C; LAMAGNERE JP; JAUBERT J; VASSELOM C; LEBLAY R; JACOMY D; GROSBOIS B; DREYFUS B; GUILHOT F; VAUGIER G; SOUTEYRAND P; LEPEU G; TOUCHIAS AM; BOUDJERRA N; BORDESSOULE M; TRAVADE P; SCHMIDT J; FACQUETDANIS J; SEBBAN C; ALLARD C; ROUSSET T; NAVARRO M; SCHVED JF; ARNAUD A; CASASSUS P; LEPRISE PY; DOR JF; TURPIN F; SOLALCELIGNY P; TERTIAN G; BERNARD JF; JAMES JM; REIGNER A; BLANC M; RAPP MJ; BOURGEOIS JP; LEJEUNE F; SALLES B; RENOUX M; GARIN B; CAMP J; TCHERNIA G; CECCALDI J; DEVIDAS A; LEMEVELLEPOURHIET A; BRIERE J; JANVIER M; NAJEAN Y; KERNEIS Y; COIFFIE B; DIGHIERO G; TEILLET F; GARNIER; DOIRON; STOPPA; ROGE; MAIGRE M; MAISONNEUVE; DIVINE M; CHERON; RODON; SIMON; THYSS; BRION A; EGHBALI; CHRISTIAN; CARDE; AUTRAND; PAITEL; SELIGMANN M; VIGNERON
    TREATMENT OF CHRONIC LYMPHOCYTIC-LEUKEMIA
    Bailliere's clinical haematology
    
    J.L. Binet et al., "TREATMENT OF CHRONIC LYMPHOCYTIC-LEUKEMIA", Bailliere's clinical haematology, 6(4), 1993, pp. 867-878
88. FAIN O; TALEB C; FRILAY Y; AUROUSSEAU MH; LEJEUNE F; THOMAS M
    THROMBOCYTOPENIC PURPURA CAUSED BY PROXIBARBAL
    La Revue de medecine interne
    
    O. Fain et al., "THROMBOCYTOPENIC PURPURA CAUSED BY PROXIBARBAL", La Revue de medecine interne, 14(5), 1993, pp. 356-356
89. FENAUX P; BINET JL; MALOUM K; LEPORRIER M; RAPP MJ; PIGUET H; BRION A; BOUDJERRA N; DREYFUS B; LEBLAY R; STOPPA AM; AUTRAND JP; SEBBAN C; PAITEL JF; MAISONNEUVE P; ROUSSET T; LINASSIER M; BRICE P; TRAVADE P; DIVINE M; DESABLENS B; JAUBERT J; ALLARD C; CHERON D; EGHBALI JP; CELIGNY PS; BORDESSOULE D; PIGNON B; VAUGIER G; LEJEUNE F; SALLES B; DEVIDAS M; BLANC M; MAIGRE M; REIGNER A; SIMON P; CHRISTIAN B; SCHVED JF; DOIRON P; RODON M; CARDE P; YAKOUB I; SOUTEYRAND P; RENOUX M; FACQUETDANIS J; HAMIDOU M; TURPIN F; DOR JF; FERMAND JP; VIGNERON N; GARNIER A; LELOSTER JP; CHEVRET S; CHASTING C
    COMPARISON OF FLUDARABINE, CYCLOPHOSPHAMIDE DOXORUBICIN PREDNISONE, AND CYCLOPHOSPHAMIDE DOXORUBICIN VINCRISTINE PREDNISONE IN ADVANCED FORMS OF CHRONIC LYMPHOCYTIC-LEUKEMIA - PRELIMINARY-RESULTS OF A CONTROLLED CLINICAL-TRIAL
    Seminars in oncology
    
    P. Fenaux et al., "COMPARISON OF FLUDARABINE, CYCLOPHOSPHAMIDE DOXORUBICIN PREDNISONE, AND CYCLOPHOSPHAMIDE DOXORUBICIN VINCRISTINE PREDNISONE IN ADVANCED FORMS OF CHRONIC LYMPHOCYTIC-LEUKEMIA - PRELIMINARY-RESULTS OF A CONTROLLED CLINICAL-TRIAL", Seminars in oncology, 20(5), 1993, pp. 21-23
90. ECLACHE V; LUSINA D; LEJEUNE F; CASASSUS P; SMADJA N; LORTHOLARY P
    PLASMA-CELL LEUKEMIA MIMICKING ACUTE MONOCYTIC LEUKEMIA IN THE COURSEOF MULTIPLE-MYELOMA
    Nouvelle revue francaise d'hematologie
    
    V. Eclache et al., "PLASMA-CELL LEUKEMIA MIMICKING ACUTE MONOCYTIC LEUKEMIA IN THE COURSEOF MULTIPLE-MYELOMA", Nouvelle revue francaise d'hematologie, 35(4), 1993, pp. 419-422
91. DELMARMOL V; SOLANO F; SELS A; HUEZ G; LIBERT A; LEJEUNE F; GHANEM G
    GLUTATHIONE DEPLETION INCREASES TYROSINASE ACTIVITY IN HUMAN-MELANOMACELLS
    Journal of investigative dermatology
    
    V. Delmarmol et al., "GLUTATHIONE DEPLETION INCREASES TYROSINASE ACTIVITY IN HUMAN-MELANOMACELLS", Journal of investigative dermatology, 101(6), 1993, pp. 871-874
92. LEJEUNE F; RIVET JM; GOBERT A; CANTON H; MILLAN MJ
    WAY-100,135 AND (-)-TERTATOLOL ACT AS ANTAGONISTS AT BOTH 5-HT(1A) AUTORECEPTORS AND POSTSYNAPTIC 5-HT(1A) RECEPTORS IN-VIVO
    European journal of pharmacology
    
    F. Lejeune et al., "WAY-100,135 AND (-)-TERTATOLOL ACT AS ANTAGONISTS AT BOTH 5-HT(1A) AUTORECEPTORS AND POSTSYNAPTIC 5-HT(1A) RECEPTORS IN-VIVO", European journal of pharmacology, 240(2-3), 1993, pp. 307-310
93. BEGUIN Y; LOO M; RZIK S; SAUTOIS B; LEJEUNE F; RORIVE G; FILLET G
    EARLY PREDICTION OF RESPONSE TO RECOMBINANT-HUMAN-ERYTHROPOIETIN IN PATIENTS WITH THE ANEMIA OF RENAL-FAILURE BY SERUM TRANSFERRIN RECEPTORAND FIBRINOGEN
    Blood
    
    Y. Beguin et al., "EARLY PREDICTION OF RESPONSE TO RECOMBINANT-HUMAN-ERYTHROPOIETIN IN PATIENTS WITH THE ANEMIA OF RENAL-FAILURE BY SERUM TRANSFERRIN RECEPTORAND FIBRINOGEN", Blood, 82(7), 1993, pp. 2010-2016
94. TURLURE P; LEPRISE PY; LETORTOREC S; LINASSIER C; IFRAH N; DESABLENS B; TOURANI JM; LEJEUNE F; SENSEBE L; BRIERE JB
    ESSENTIAL THROMBOCYTHEMIA (ET) CLINICAL COURSE AND RESULTS OF A MULTICENTER PROSPECTIVE-STUDY
    Blood
    
    P. Turlure et al., "ESSENTIAL THROMBOCYTHEMIA (ET) CLINICAL COURSE AND RESULTS OF A MULTICENTER PROSPECTIVE-STUDY", Blood, 82(10), 1993, pp. 10000197-10000197
95. LEYVRAZ S; KETTERER N; VUICHARD P; VONFLIEDNER V; LEJEUNE F; SCHNEIDER P; GROB JP; BACHMANN F
    SEQUENTIAL HIGH-DOSE COMBINATION CHEMOTHERAPY WITH GRANULOCYTE-COLONY-STIMULATING FACTOR AND PERIPHERAL-BLOOD PROGENITOR CELLS IN PATIENTS WITH SOLID TUMORS - INTENSIFICATION LIMITED BY NONHEMATOLOGIC TOXIC EFFECTS
    Journal of the National Cancer Institute
    
    S. Leyvraz et al., "SEQUENTIAL HIGH-DOSE COMBINATION CHEMOTHERAPY WITH GRANULOCYTE-COLONY-STIMULATING FACTOR AND PERIPHERAL-BLOOD PROGENITOR CELLS IN PATIENTS WITH SOLID TUMORS - INTENSIFICATION LIMITED BY NONHEMATOLOGIC TOXIC EFFECTS", Journal of the National Cancer Institute, 85(23), 1993, pp. 1962-1964